Monoclonal antibody · Antagonist of CD73 (ecto-5'-nucleotidase) (NT5E) · developed by ASTRAZENECA
Oleclumab is a monoclonal antibody that binds CD73, also known as ecto-5'-nucleotidase, a membrane enzyme that converts AMP to adenosine. Binding causes CD73 to cluster and internalize, reducing extracellular adenosine and its suppression of lymphocytes. It is being studied in triple negative breast neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03742102 | Phase 1/2 | Triple Negative Breast Neoplasms | Active not recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Triple Negative Breast Neoplasms
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →